NDA - ANDA Pidduck is talking about two approval processes here ?
Or am I misunderstanding something ?
David Pidduck Yes. We thought it was important to update investors on some of the work that we've done. I think, MediPharm is probably a global leader in the characterization of pharmaceutical CBD. And with that, and with our Drug Establishment License, and with our drug master file with the U.S. FDA, it gives us an opportunity to supply API to pharmaceutical companies.
So in Q3, we provided API for new novel drug applications, which are very long by nature,
as well as abbreviated new drug application. And abbreviated new drug application is basically a generic application. So our pharmaceutical partner is targeting current pharmaceutical drugs with cannabinoids and API, and they're filing a generic for that. We are being a little bit restrictive in some of the information that we're doing. There's a competitive advantage of not fully disclosing as our pharmaceutical partner would prefer that we don't get into too much detail. But as the file makes its way through the process, we will be able to continue to update all of our stakeholders.